Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors

von Zang, Yan, Kirk, Christopher J, Johnson, Daniel E
Veröffentlicht 2014

Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle.

von Barker, Christopher J, Wright, Joanne, Hughes, Philip J, Kirk, Christopher J, Michell, Robert H
Veröffentlicht 2004

Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis

von Basler, Michael, Mundt, Sarah, Muchamuel, Tony, Moll, Carlo, Jiang, Jing, Groettrup, Marcus, Kirk, Christopher J
Veröffentlicht 2014

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

von Suzuki, Erika, Demo, Susan, Deu, Edgar, Keats, Jonathan, Arastu-Kapur, Shirin, Bergsagel, P. Leif, Bennett, Mark K., Kirk, Christopher J.
Veröffentlicht 2011

PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7, Blocks Multiple Myeloma Cell Growth both in Vitro and in Vivo

von Singh, Ajita V., Bandi, Madhavi, Aujay, Monette A, Kirk, Christopher J, Hark, David E., Raje, Noopur, Chauhan, Dharminder, Anderson, Kenneth C.
Veröffentlicht 2010

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

von Chauhan, Dharminder, Singh, Ajita V., Aujay, Monette, Kirk, Christopher J., Bandi, Madhavi, Ciccarelli, Bryan, Raje, Noopur, Richardson, Paul, Anderson, Kenneth C.
Veröffentlicht 2010

Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities are Enhanced by Suppression of Mcl-1 or Autophagy

von Zang, Yan, Thomas, Sufi M., Chan, Elena T., Kirk, Christopher J., Freilino, Maria L., DeLancey, Hannah M., Grandis, Jennifer R., Li, Changyou, Johnson, Daniel E.
Veröffentlicht 2012

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4

von Zang, Yan, Thomas, Sufi M., Chan, Elena T., Kirk, Christopher J., Freilino, Maria L., DeLancey, Hannah M., Grandis, Jennifer R., Li, Changyou, Johnson, Daniel E.
Veröffentlicht 2012

Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity

von Li, Hao, Ponder, Elizabeth L., Verdoes, Martijn, Asbjornsdottir, Kristijana H., Deu, Edgar, Edgington, Laura E., Lee, Jeong Tae, Kirk, Christopher J., Demo, Susan D., Williamson, Kim C., Bogyo, Matthew
Veröffentlicht 2012

Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus via the dual inhibition of Type I Interferon and autoantibody secreting cells

von Ichikawa, H. Travis, Conley, Thomas, Muchamuel, Tony, Jiang, Jing, Lee, Susan, Owen, Teresa, Barnard, Jennifer, Nevarez, Sarah, Goldman, Bruce I., Kirk, Christopher J., Looney, R. John, Anolik, Jennifer H.
Veröffentlicht in Arthritis Rheum (2012)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

von Niewerth, Denise, Kaspers, Gertjan JL, Assaraf, Yehuda G, van Meerloo, Johan, Kirk, Christopher J, Anderl, Janet, Blank, Jonathan L, van de Ven, Peter M, Zweegman, Sonja, Jansen, Gerrit, Cloos, Jacqueline
Veröffentlicht 2014

Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

von Basler, Michael, Lindstrom, Michelle M, LaStant, Jacob J, Bradshaw, J Michael, Owens, Timothy D, Schmidt, Christian, Maurits, Elmer, Tsu, Christopher, Overkleeft, Herman S, Kirk, Christopher J, Langrish, Claire L, Groettrup, Marcus
Veröffentlicht in EMBO Rep (2018)

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

von Niewerth, Denise, Franke, Niels E., Jansen, Gerrit, Assaraf, Yehuda G., van Meerloo, Johan, Kirk, Christopher J., Degenhardt, Jeremiah, Anderl, Janet, Schimmer, Aaron D., Zweegman, Sonja, de Haas, Valerie, Horton, Terzah M., Kaspers, Gertjan J.L., Cloos, Jacqueline
Veröffentlicht 2013

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

von Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
Veröffentlicht in Br J Haematol (2016)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

von Verbrugge Sue Ellen, Al Marjon, Assaraf Yehuda G, Niewerth Denise, van Meerloo Johan, Cloos Jacqueline, van der Veer Michael, Scheffer George L, Peters Godefridus J, Chan Elena T, Anderl Janet L, Kirk Christopher J, Zweegman Sonja, Dijkmans Ben AC, Lems Willem F, Scheper Rik J, de Gruijl Tanja D, Jansen Gerrit
Veröffentlicht 2013-01-01

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

von Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G, Niewerth, Denise, van Meerloo, Johan, Cloos, Jacqueline, van der Veer, Michael, Scheffer, George L, Peters, Godefridus J, Chan, Elena T, Anderl, Janet L, Kirk, Christopher J, Zweegman, Sonja, Dijkmans, Ben AC, Lems, Willem F, Scheper, Rik J, de Gruijl, Tanja D, Jansen, Gerrit
Veröffentlicht 2013